Johannesburg – Ascendis Health [JSE:ASC] has finalised a number of European acquisitions in recent months which are expected to boost profit margins in 2018.
This is according to a statement issued by the JSE-listed pharmaceutical company on Monday. The company unpacked its two new European acquisitions.
Recently Ascendis Health had concluded its acquisition of Cipla Agrimed SA and Cipla Vet SA for R375m. This acquisition officially became unconditional on June 1 and is expected to help Ascendis expand into the veterinary pharma market and assist the company’s international strategy through expansions into new African markets.